CYBERONICS' NCP DEVICE FOR EPILEPSY INITIAL COMMERCIAL IMPLANT SET FOR JULY 24; FDA APPROVAL COMES LESS THAN THREE WEEKS AFTER PANEL REVIEW
This article was originally published in The Gray Sheet
Executive Summary
The first commercial implant of Cyberonics' NeuroCybernetic Prosthesis (NCP) system is slated for July 24 following FDA's July 16 approval of a premarket approval application for the implantable vagus nerve stimulator for treating epilepsy.
You may also be interested in...
NeuroCybernetic Prosthesis Safe and Effective For Epilepsy - AAN Panel
Cyberonics NeuroCybernetic Prosthesis vagal nerve stimulation (VNS) device is safe and effective for the treatment of epilepsy, the American Academy of Neurology's Therapeutic and Technology Subcommittee declares in the Sept. 11 issue of the journal Neurology.
NeuroCybernetic Prosthesis Safe and Effective For Epilepsy - AAN Panel
Cyberonics NeuroCybernetic Prosthesis vagal nerve stimulation (VNS) device is safe and effective for the treatment of epilepsy, the American Academy of Neurology's Therapeutic and Technology Subcommittee declares in the Sept. 11 issue of the journal Neurology.
Cyberonics Seeking Federal Support For NCP Depression Pivotal Trial
Cyberonics' NCP NeuroCybernetic Prosthesis system eliminated symptoms of major depressive episodes in at least 25% of patients having completed the acute phase of a pilot study evaluating the vagus nerve stimulation therapy for major chronic depression.